Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis

Puay Wah Phuan, Baoxue Yang, John M. Knapp, Alex B. Wood, Gergely L. Lukacs, Mark J. Kurth, Alan S. Verkman

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The ΔPhe508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein impairs its folding, stability, and chloride channel gating. Although small molecules that separately correct defective ΔPhe508-CFTR folding/cellular processing ("correctors") or chloride channel gating ("potentiators") have been discovered and are in clinical trials, single compounds with bona fide dual corrector and potentiator activities have not been identified. Here, screening of ∼110,000 small molecules not tested previously revealed a cyanoquinoline class of compounds with independent corrector and potentiator activities (termed CoPo). Analysis of 180 CoPo analogs revealed 6 compounds with dual corrector and potentiator activities and 13 compounds with only potentiator activity. N-(2-((3-Cyano-5,7-dimethylquinolin-2- yl)amino)ethyl)-3-methoxybenzamide (CoPo-22), which was synthesized in six steps in 52% overall yield, had low micromolar EC50 for ΔPhe508-CFTR corrector and potentiator activities by short-circuit current assay. Maximal corrector and potentiator activities were comparable with those conferred by the bithiazole Corr-4a and the flavone genistein, respectively. CoPo-22 also activated wild-type and G551D CFTR chloride conductance within minutes in a forskolin-dependent manner. Compounds with dual corrector and potentiator activities may be useful for singledrug treatment of cystic fibrosis caused by ΔPhe508 mutation.

Original languageEnglish (US)
Pages (from-to)683-693
Number of pages11
JournalMolecular Pharmacology
Volume80
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Chloride Channels
Cystic Fibrosis
flavone
Mutation
Genistein
Colforsin
Chlorides
Clinical Trials
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. / Phuan, Puay Wah; Yang, Baoxue; Knapp, John M.; Wood, Alex B.; Lukacs, Gergely L.; Kurth, Mark J.; Verkman, Alan S.

In: Molecular Pharmacology, Vol. 80, No. 4, 10.2011, p. 683-693.

Research output: Contribution to journalArticle

Phuan, Puay Wah ; Yang, Baoxue ; Knapp, John M. ; Wood, Alex B. ; Lukacs, Gergely L. ; Kurth, Mark J. ; Verkman, Alan S. / Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. In: Molecular Pharmacology. 2011 ; Vol. 80, No. 4. pp. 683-693.
@article{e6eba864c362434390cb941f297b1d82,
title = "Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis",
abstract = "The ΔPhe508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein impairs its folding, stability, and chloride channel gating. Although small molecules that separately correct defective ΔPhe508-CFTR folding/cellular processing ({"}correctors{"}) or chloride channel gating ({"}potentiators{"}) have been discovered and are in clinical trials, single compounds with bona fide dual corrector and potentiator activities have not been identified. Here, screening of ∼110,000 small molecules not tested previously revealed a cyanoquinoline class of compounds with independent corrector and potentiator activities (termed CoPo). Analysis of 180 CoPo analogs revealed 6 compounds with dual corrector and potentiator activities and 13 compounds with only potentiator activity. N-(2-((3-Cyano-5,7-dimethylquinolin-2- yl)amino)ethyl)-3-methoxybenzamide (CoPo-22), which was synthesized in six steps in 52{\%} overall yield, had low micromolar EC50 for ΔPhe508-CFTR corrector and potentiator activities by short-circuit current assay. Maximal corrector and potentiator activities were comparable with those conferred by the bithiazole Corr-4a and the flavone genistein, respectively. CoPo-22 also activated wild-type and G551D CFTR chloride conductance within minutes in a forskolin-dependent manner. Compounds with dual corrector and potentiator activities may be useful for singledrug treatment of cystic fibrosis caused by ΔPhe508 mutation.",
author = "Phuan, {Puay Wah} and Baoxue Yang and Knapp, {John M.} and Wood, {Alex B.} and Lukacs, {Gergely L.} and Kurth, {Mark J.} and Verkman, {Alan S.}",
year = "2011",
month = "10",
doi = "10.1124/mol.111.073056",
language = "English (US)",
volume = "80",
pages = "683--693",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis

AU - Phuan, Puay Wah

AU - Yang, Baoxue

AU - Knapp, John M.

AU - Wood, Alex B.

AU - Lukacs, Gergely L.

AU - Kurth, Mark J.

AU - Verkman, Alan S.

PY - 2011/10

Y1 - 2011/10

N2 - The ΔPhe508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein impairs its folding, stability, and chloride channel gating. Although small molecules that separately correct defective ΔPhe508-CFTR folding/cellular processing ("correctors") or chloride channel gating ("potentiators") have been discovered and are in clinical trials, single compounds with bona fide dual corrector and potentiator activities have not been identified. Here, screening of ∼110,000 small molecules not tested previously revealed a cyanoquinoline class of compounds with independent corrector and potentiator activities (termed CoPo). Analysis of 180 CoPo analogs revealed 6 compounds with dual corrector and potentiator activities and 13 compounds with only potentiator activity. N-(2-((3-Cyano-5,7-dimethylquinolin-2- yl)amino)ethyl)-3-methoxybenzamide (CoPo-22), which was synthesized in six steps in 52% overall yield, had low micromolar EC50 for ΔPhe508-CFTR corrector and potentiator activities by short-circuit current assay. Maximal corrector and potentiator activities were comparable with those conferred by the bithiazole Corr-4a and the flavone genistein, respectively. CoPo-22 also activated wild-type and G551D CFTR chloride conductance within minutes in a forskolin-dependent manner. Compounds with dual corrector and potentiator activities may be useful for singledrug treatment of cystic fibrosis caused by ΔPhe508 mutation.

AB - The ΔPhe508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein impairs its folding, stability, and chloride channel gating. Although small molecules that separately correct defective ΔPhe508-CFTR folding/cellular processing ("correctors") or chloride channel gating ("potentiators") have been discovered and are in clinical trials, single compounds with bona fide dual corrector and potentiator activities have not been identified. Here, screening of ∼110,000 small molecules not tested previously revealed a cyanoquinoline class of compounds with independent corrector and potentiator activities (termed CoPo). Analysis of 180 CoPo analogs revealed 6 compounds with dual corrector and potentiator activities and 13 compounds with only potentiator activity. N-(2-((3-Cyano-5,7-dimethylquinolin-2- yl)amino)ethyl)-3-methoxybenzamide (CoPo-22), which was synthesized in six steps in 52% overall yield, had low micromolar EC50 for ΔPhe508-CFTR corrector and potentiator activities by short-circuit current assay. Maximal corrector and potentiator activities were comparable with those conferred by the bithiazole Corr-4a and the flavone genistein, respectively. CoPo-22 also activated wild-type and G551D CFTR chloride conductance within minutes in a forskolin-dependent manner. Compounds with dual corrector and potentiator activities may be useful for singledrug treatment of cystic fibrosis caused by ΔPhe508 mutation.

UR - http://www.scopus.com/inward/record.url?scp=80053179441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053179441&partnerID=8YFLogxK

U2 - 10.1124/mol.111.073056

DO - 10.1124/mol.111.073056

M3 - Article

VL - 80

SP - 683

EP - 693

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -